Corvia Medical Secures $55 Million to Propel Heart Failure Device Approval Process

Corvia Medical Closes $55 Million Funding Round



In a significant move to push the boundaries of heart failure treatment, Corvia Medical, Inc. recently announced the successful completion of a $55 million funding round. This essential financial boost is anticipated to contribute directly to the ongoing RESPONDER-HF trial, a rigorous clinical study pivotal for the development of their innovative Corvia Atrial Shunt.

The Funding Breakdown


The funds have been secured from a group of prominent existing investors, including the likes of Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and several strategic partners. This funding will specifically aid in completing the international RESPONDER-HF trial, which is a double-blinded, randomized, sham-controlled, confirmatory study currently being conducted across over 65 institutions worldwide and spanning three continents.

CEO George Fazio expressed gratitude for the steadfast support from their investors, emphasizing that such collaboration is crucial for advancing towards FDA submission for the Corvia Atrial Shunt. He remarked, “Their commitment furthers our mission to bring this transformative heart failure treatment to millions of patients worldwide.”

Why the Corvia Atrial Shunt Matters


Heart failure is a profound global challenge, affecting over 26 million individuals worldwide. Among these, the majority suffer from heart failure with preserved ejection fraction (HFpEF), which represents a critical unmet clinical need in cardiovascular care. The Corvia Atrial Shunt aims to mitigate elevated left atrial pressure (LAP)—the core contributor to heart failure symptoms—by establishing a passage between the left and right atria, thus alleviating heart failure events and enhancing patient quality of life.

Originally granted Breakthrough Device designation by the FDA in 2019, the Corvia Atrial Shunt is at the forefront of a potential revolutionary shift in heart failure management. As described, the results from the RESPONDER-HF trial are expected to generate crucial clinical data needed for FDA approval.

Moving Forward with Optimism


Paul LaViolette, Chair of Corvia’s Board, echoed Fazio’s sentiments, stating, “We firmly believe Corvia has the potential to fundamentally alter the landscape of heart failure treatment, and our investors share that vision. With these resources, we are well-equipped to drive the company through the approval process and introduce this groundbreaking therapy to the market.”

In summary, Corvia Medical’s efforts to secure this latest funding are not only a financial achievement but a hopeful endeavor to enhance and transform treatments available for heart failure patients. As the RESPONDER-HF trial progresses, the healthcare community and patients alike eagerly watch for the outcomes that could change lives globally.

For more information on the RESPONDER-HF trial and eligibility, please visit Corvia Medical.

About Corvia Medical, Inc.


Founded in 2009 and headquartered in Tewksbury, Massachusetts, Corvia Medical, Inc. is striving to redefine the standard of care in heart failure management through innovative transcatheter cardiovascular devices. For further details, visit Corvia Medical.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.